Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hurdles on the road to personalized medicine.

Literature DB >> 25226812

Hurdles on the road to personalized medicine.

Abstract

Cancer treatment is slowly shifting from an approach in which the tissue of origin and the histology were the guiding principles for the choice of chemotherapy towards a genotype-centric approach in which the changes in the cancer genome are used to select patients for treatment with highly selective and targeted drugs. This transition has all the hallmarks of a disruptive innovation and requires major adjustments in the way that cancer is diagnosed and treated. We discuss here the hurdles on the road ahead to a more personalized treatment of cancer.

Entities: Chemical

Keywords: Drug development; Personalized medicine; Targeted therapy

Mesh：

Year: 2014 PMID： 25226812 PMCID： PMC5528743 DOI： 10.1016/j.molonc.2014.08.009

Source DB: PubMed Journal: Mol Oncol ISSN： 1574-7891 Impact factor: 6.603

26 in total

1. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors: Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal: Nature Date: 2012-01-26 Impact factor: 49.962

2. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors: Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal: N Engl J Med Date: 2004-12-10 Impact factor: 91.245

3. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.

Authors: Xuelin Huang; Jorge Cortes; Hagop Kantarjian
Journal: Cancer Date: 2012-01-31 Impact factor: 6.860

4. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.

Authors: Felipe De Sousa E Melo; Xin Wang; Marnix Jansen; Evelyn Fessler; Anne Trinh; Laura P M H de Rooij; Joan H de Jong; Onno J de Boer; Ronald van Leersum; Maarten F Bijlsma; Hans Rodermond; Maartje van der Heijden; Carel J M van Noesel; Jurriaan B Tuynman; Evelien Dekker; Florian Markowetz; Jan Paul Medema; Louis Vermeulen
Journal: Nat Med Date: 2013-04-14 Impact factor: 53.440

5. Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors: I Bernard Weinstein
Journal: Science Date: 2002-07-05 Impact factor: 47.728

6. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.

Authors: Muhammed Murtaza; Sarah-Jane Dawson; Dana W Y Tsui; Davina Gale; Tim Forshew; Anna M Piskorz; Christine Parkinson; Suet-Feung Chin; Zoya Kingsbury; Alvin S C Wong; Francesco Marass; Sean Humphray; James Hadfield; David Bentley; Tan Min Chin; James D Brenton; Carlos Caldas; Nitzan Rosenfeld
Journal: Nature Date: 2013-04-07 Impact factor: 49.962

7. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Authors: Andrea Bertotti; Giorgia Migliardi; Francesco Galimi; Francesco Sassi; Davide Torti; Claudio Isella; Davide Corà; Federica Di Nicolantonio; Michela Buscarino; Consalvo Petti; Dario Ribero; Nadia Russolillo; Andrea Muratore; Paolo Massucco; Alberto Pisacane; Luca Molinaro; Emanuele Valtorta; Andrea Sartore-Bianchi; Mauro Risio; Lorenzo Capussotti; Marcello Gambacorta; Salvatore Siena; Enzo Medico; Anna Sapino; Silvia Marsoni; Paolo M Comoglio; Alberto Bardelli; Livio Trusolino
Journal: Cancer Discov Date: 2011-09-02 Impact factor: 39.397

8. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors: Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal: Nature Date: 2012-06-28 Impact factor: 49.962

9. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer.

Authors: Eva Budinska; Vlad Popovici; Sabine Tejpar; Giovanni D'Ario; Nicolas Lapique; Katarzyna Otylia Sikora; Antonio Fabio Di Narzo; Pu Yan; John Graeme Hodgson; Scott Weinrich; Fred Bosman; Arnaud Roth; Mauro Delorenzi
Journal: J Pathol Date: 2013-07-08 Impact factor: 7.996

10. Discovery and saturation analysis of cancer genes across 21 tumour types.

Authors: Michael S Lawrence; Petar Stojanov; Craig H Mermel; James T Robinson; Levi A Garraway; Todd R Golub; Matthew Meyerson; Stacey B Gabriel; Eric S Lander; Gad Getz
Journal: Nature Date: 2014-01-05 Impact factor: 49.962

8 in total

Review 1. Prioritizing therapeutic targets using patient-derived xenograft models.

Authors: K A Lodhia; A M Hadley; P Haluska; C L Scott
Journal: Biochim Biophys Acta Date: 2015-03-14

2. Is Whole-Exome Sequencing an Ethically Disruptive Technology? Perspectives of Pediatric Oncologists and Parents of Pediatric Patients With Solid Tumors.

Authors: Laurence B McCullough; Melody J Slashinski; Amy L McGuire; Richard L Street; Christine M Eng; Richard A Gibbs; D William Parsons; Sharon E Plon
Journal: Pediatr Blood Cancer Date: 2015-10-27 Impact factor: 3.167

3. Integrating precision cancer medicine into healthcare-policy, practice, and research challenges.

Authors: Gabrielle Bertier; Jian Carrot-Zhang; Vassilis Ragoussis; Yann Joly
Journal: Genome Med Date: 2016-10-24 Impact factor: 11.117

Review 4. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.

Authors: Gaowei Fan; Kuo Zhang; Jiansheng Ding; Jinming Li
Journal: Oncotarget Date: 2017-05-16